PMID- 9815812
OWN - NLM
STAT- MEDLINE
DCOM- 19990225
LR  - 20191210
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 3
IP  - 8
DP  - 1997 Aug
TI  - Vitronectin binding to urokinase receptor in human breast cancer.
PG  - 1299-308
AB  - Functional assembly of the plasminogen-dependent proteolytic system on the cell 
      surface requires multiple interactions involving urokinase (uPA), urokinase 
      receptor (uPAR), plasminogen activator inhibitors, and other molecules that 
      mediate cell migration and adhesion. We analyzed the in vitro interaction of 
      uPAR-containing particulate cell fractions with the amino-terminal fragment (ATF) 
      of human urokinase and the matrix-like form of vitronectin. Binding and 
      cross-linking of 125I-labeled ATF to crude membrane extracts from LB6-19 mouse 
      cells overexpressing human uPARs in the presence of 25 nM urea-denatured 
      vitronectin led to the formation of Mr 137,000, 92, 000, and 82,000 covalent 
      complexes. Immunoprecipitation of the preformed cross-linked 125I-labeled 
      complexes with anti-vitronectin, anti-uPA, or anti-uPAR antibodies revealed that 
      the Mr 82,000 and 92, 000 species do contain ATF and vitronectin and identified 
      the Mr 137, 000 species as a ternary complex formed by ATF, uPAR, and 
      vitronectin. A similar electrophoretic pattern was displayed by acid-pretreated 
      membranes extracted from MCF-7 breast carcinoma or HT1080 fibrosarcoma cell 
      lines, as well as a ductal breast carcinoma specimen; the latter exhibited 
      complex formation at concentrations of vitronectin lower than 10 nM. Finally, 
      uPAR-vitronectin interaction was further documented by the decreased reactivity 
      of an anti-uPAR polyclonal antibody to acid-pretreated sections of 10 breast 
      carcinomas that had been preincubated with vitronectin. Our findings highlight 
      the ability of uPAR to interact simultaneously with vitronectin and uPA in breast 
      cancer, supporting a dynamic coupling of the molecular mechanisms underlying 
      plasminogen-dependent matrix degradation and cell adhesion.
FAU - Carriero, M V
AU  - Carriero MV
AD  - Istituto Nazionale per lo Studio e la Cura dei Tumori, Via M. Semmola.
FAU - Del Vecchio, S
AU  - Del Vecchio S
FAU - Franco, P
AU  - Franco P
FAU - Potena, M I
AU  - Potena MI
FAU - Chiaradonna, F
AU  - Chiaradonna F
FAU - Botti, G
AU  - Botti G
FAU - Stoppelli, M P
AU  - Stoppelli MP
FAU - Salvatore, M
AU  - Salvatore M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (PLAUR protein, human)
RN  - 0 (Peptide Fragments)
RN  - 0 (Plaur protein, mouse)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (Receptors, Urokinase Plasminogen Activator)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Vitronectin)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
SB  - IM
MH  - Animals
MH  - Breast Neoplasms/*metabolism
MH  - Cell Adhesion
MH  - Female
MH  - Humans
MH  - Kinetics
MH  - L Cells
MH  - Mice
MH  - Peptide Fragments/*metabolism
MH  - Protein Denaturation
MH  - Receptors, Cell Surface/*metabolism
MH  - Receptors, Urokinase Plasminogen Activator
MH  - Recombinant Proteins/metabolism
MH  - Transfection
MH  - Tumor Cells, Cultured
MH  - Urokinase-Type Plasminogen Activator/*metabolism
MH  - Vitronectin/*metabolism
EDAT- 1997/08/01 00:00
MHDA- 1998/11/17 00:01
CRDT- 1997/08/01 00:00
PHST- 1997/08/01 00:00 [pubmed]
PHST- 1998/11/17 00:01 [medline]
PHST- 1997/08/01 00:00 [entrez]
PST - ppublish
SO  - Clin Cancer Res. 1997 Aug;3(8):1299-308.